Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations

Q: What does this research mean for the field?

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) provides durable long-term virologic suppression in people with HIV who harbor resistance-associated mutations, including those with M184V/I and additional NRTI mutations. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Cinthia S. Lamaizón; Diego Cecchini; Martin Brizuela; Gastón Copertari; Brenda Bacelar; Macarena Roel; Edgardo Bottaro; Lidia I. Cassetti

doi:10.1097/qad.0000000000004553

August 26, 2026AIDS

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the long-term virologic outcomes over 4 years in people with HIV harboring resistance-associated mutations after switching to bictegravir/emtricitabine/tenofovir alafenamide.
Conducted a real-world cohort study of people with HIV harboring resistance-associated mutations (RAMs) who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).
Evaluated virologic suppression over 4 years of follow-up across resistance subgroups, including M184V/I with additional nucleoside reverse transcriptase inhibitor (NRTI)-RAMs and by genotypic susceptibility score (GSS).
Virologic suppression remained durable and sustained across diverse resistance profiles throughout the 4-year follow-up period without numerical rates provided.
Effectiveness remained robust across subgroups with M184V/I plus additional NRTI-RAMs and across different genotypic susceptibility score strata.

Implication

Cohort study demonstrates sustained virologic suppression in people with drug-resistant HIV, supporting the regimen's long-term clinical utility.

Abstract

Resistance-associated mutations (RAMs) limit treatment options for HIV. We evaluated virologic outcomes in people with HIV harboring RAMs who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a real-world cohort during 4 years of follow-up. Virologic suppression was sustained across RAM subgroups, including M184V/I with additional nucleoside reverse transcriptase inhibitor (NRTI)-RAMs. Stratification by genotypic susceptibility score (GSS) suggests robust effectiveness. B/F/TAF demonstrates durable long-term suppression in different resistance profiles, supporting its use in this population.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lamaizón et al. (2026) studied this question.

synapsesocial.com/papers/6a9299338e5d7d1fc0c10f2e https://doi.org/10.1097/qad.0000000000004553

View Full Paper

Ask AI

Bookmark

Share

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations

Key Points

Implication

Abstract

Discussion

Cite This Study

Long-term effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and resistance-associated mutations

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading